Thus, we investigated the expression of the tumor markers c-MET, RhoA, and CLDN18 by immunohistochemistry (IHC) in a large and extensively characterized Western cohort of resected GC and its correlation with clinicopathological characteristics and survival outcomes. The gene discussed is CLDN18; the disease is neoplasm.